Moderna (NASDAQ:MRNA – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 EPS.
Moderna Stock Down 0.5 %
Shares of NASDAQ:MRNA traded down $0.59 on Friday, reaching $125.00. The company had a trading volume of 4,512,362 shares, compared to its average volume of 4,144,759. The stock has a market capitalization of $47.86 billion, a P/E ratio of -10.07 and a beta of 1.57. The stock has a 50-day moving average price of $105.05 and a 200 day moving average price of $94.37. Moderna has a twelve month low of $62.55 and a twelve month high of $142.79. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.
Insider Activity at Moderna
In other Moderna news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,954 shares of company stock valued at $14,822,576. Corporate insiders own 15.70% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Research Report on MRNA
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- Investing In Preferred Stock vs. Common Stock
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Consumer Staples Stocks, Explained
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.